A proprietary platform that provides a personalized comprehensive profile of the immune system
- Can be useful in anticipating attacks on the body
- Initial technology was licensed from, invented and used at Stanford University
- Pioneering Selective Tolerate (ST) therapeutic technology developed over the past 20+ years at Loma Linda University
- 8 U.S. patents and 78 foreign patents as of April 2020, 18 additional pending
- Demonstrated preclinical efficacy for Skin Grafting, Psoriasis, Type 1 Diabetes, and Alopecia Areata
AditxtReprogramming™
Immune Reprogramming Technology
We are commercializing a nucleic acid-based technology named Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way the body naturally induces tolerance to our own tissues (therapeutically induced immune tolerance). ADi™ is a technology platform which we believe can be engineered to address a wide variety of indications.
Publications
The ADi™ technology and its various components are protected by multiple families of patents and patent applications, including several U.S. and non-U.S. issued patents.
About ADITXT
We are a life sciences company developing technologies specifically focused on improving the health of the immune system through monitoring and immune reprogramming.